Avita Medical Limited is a medical technology company. The principal activities of the Company are the commercialization of its regenerative product. The Company has three segments: the Asia Pacific region; the Americas, including Canada, and the Europe, Middle East and Africa (EMEA) region. It develops and distributes regenerative products for the treatment of a range of wounds, scars and skin defects. Its collection and application technology provides treatment solutions derived from the regenerative properties of a patient's own skin. The Company's product, ReCell, is used in the treatment of a range of burns, plastic, reconstructive and cosmetic procedures. Its technology, Regenerative Epithelial Suspension (RES), is an autologous suspension composed of the cells and wound-healing factors necessary to regenerate natural skin. The Company also offers ReGenerCell, which is used for the treatment of wounds, and ReNovaCell, which is used for the treatment of pigmentation.